Therapeutic peptides: Historical perspectives, current development trends, and future directions.
By Jolene L. Lau, Michael K. Dunn. Bioorganic & Medicinal Chemistry, 2017
1,509 citations recorded by the source corpus.
Peptide therapeutics have played a notable role in medical practice since the advent of insulin therapy in the 1920s. Over 60 peptide drugs are approved in the United States and other major markets, and peptides continue to enter clinical development at a steady pace. Peptide drug discovery has diversified beyond its traditional focus on endogenous human peptides to include a broader range of structures identified from other natural sources or through medicinal chemistry efforts. We maintain a comprehensive dataset on peptides that have entered human clinical studies that includes over 150 peptides in active development today. Here we provide an overview of the peptide therapeutic landscape, including historical perspectives, molecular characteristics, regulatory benchmarks, and a therapeutic area breakdown.
Subfields: Computational Theory and Mathematics, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/91243fb0a41e438a7e9807feed274c2e11122be0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Nanxi Wang
- Wenping Zhang
- Xurui Cheng
- Xi Wang
- Lulu Cai
- Rehmat Islam
- Zhibin Yan
- Rui Wang
Citations in the corpus
- Therapeutic peptides: current applications and future directions (2022, background): “Phase II trial of angiotensin-(1-7) for the treatment of patients with metastatic sarcoma.”
- Smart nanoparticles for cancer therapy (2023, background): “294,295 The complex structure not only improves the activity and selectivity of peptides and proteins, but also increases the instability.”